Actively Recruiting
Comparing TACE-Lenvatinib With TACE-Lenvatinib Plus Ablation for Intermediate-Stage Recurrent Liver Cancer
Led by Sun Yat-sen University · Updated on 2024-12-03
116
Participants Needed
1
Research Sites
108 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying treatments for intermediate-stage recurrent hepatocellular carcinoma RHCC, a condition where liver cancer returns at a specific stage. This trial compares two approaches a combination of transarterial chemoembolization TACE with the drug Lenvatinib, and the same combination plus ablation therapy. The goal is to determine if adding ablation improves outcomes for patients with this type of liver cancer. The study has two groups. One group receives TACE, where a microcatheter delivers chemotherapy drugs directly to the tumors blood supply, combined with daily oral Lenvatinib doses based on body weight. The other group receives the same TACE and Lenvatinib treatment plus ablation therapy radiofrequency, microwave, or cryoablation performed 6 to 8 weeks after TACE using ultrasound or CT guidance. Success of ablation is measured by achieving an adequate margin beyond the tumor size. Participants will be monitored for at least 24 months to evaluate progression-free survival, with additional follow-up up to 36 months to observe overall survival and tumor response rates. Assessments include imaging and clinical evaluations to track tumor progression and treatment effects. The study aims to identify which patients benefit most from combining ablation with TACE and Lenvatinib, with safety and effectiveness monitored throughout the trial.
CONDITIONS
Brief Title
The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
Research Team
Q
Qunfang Zhou
F
Feng Duan
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here